1. Kor /
  2. Eng

  1. Kor /
  2. Eng

SAIHST Forum

[Prof. Juhee Cho/Prof. Danbee Kang] Long-Term Beta-Blocker Therapy After AMI Without HF (European Heart Journal. 15 Jun 2020)
Date 2020/07/03
View 244

 

 

 

 

 

 

- The Nationwide Cohort Study involved 30 thousand subjects, enrolled in the National Health Insurance Service

- Patients receiving β-blocker therapy for over one year had 20% lower risks of an all-cause death rate.

  The research team led by Prof. Joo-Yong Han, Prof. Ji-Hoon Kim from Samsung Medical Center, and Prof. Joohee Cho, Prof. Danbee Kang from SAIHST, published the newest article. They discovered that “β -blocker therapy for over one year after MI was associated with reduced all-cause death among patients with AMI without HF.”

 

 

European Heart Journal. 2020 Jun 15;ehaa376.doi: 10.1093/eurheartj/ehaa376. [Online ahead of print]

 
Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study

Jihoon Kim, Danbee Kang, Hyejeong Park, Minwoong Kang, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eliseo Guallar, Juhee Cho, Joo-Yong Hahn

 

Abstract


Aims: To investigate the association between long-term β-blocker therapy and clinical outcomes in patients without heart failure (HF) after acute myocardial infarction (AMI).  

 

Method and results: Between 2010 and 2015, a total of 28 970 patients who underwent coronary revascularization for AMI with β-blocker prescription at hospital discharge and were event-free from death, recurrent myocardial infarction (MI), or HF for 1 year were enrolled from Korean nationwide medical insurance data. The primary outcome was all-cause death. The secondary outcomes were recurrent MI, hospitalization for new HF, and a composite of all-cause death, recurrent MI, or hospitalization for new HF. Outcomes were compared between β-blocker therapy for ≥1 year (N = 22 707) and β-blocker therapy for <1 year (N = 6263) using landmark analysis at 1 year after index MI. Compared with patients receiving β-blocker therapy for <1 year, those receiving β-blocker therapy for ≥1 year had significantly lower risks of all-cause death [adjusted hazard ratio (HR) 0.81; 95% confidence interval (CI) 0.72-0.91] and composite of all-cause death, recurrent MI, or hospitalization for new HF (adjusted HR 0.82; 95% CI 0.75-0.89), but not the risks of recurrent MI or hospitalization for new HF. The lower risk of all-cause death associated with persistent β-blocker therapy was observed beyond 2 years (adjusted HR 0.86; 95% CI 0.75-0.99) but not beyond 3 years (adjusted HR 0.87; 95% CI 0.73-1.03) after MI.  

 

Conclusion: In this nationwide cohort, β-blocker therapy for ≥1 year after MI was associated with reduced all-cause death among patients with AMI without HF.  

    Keywords: Myocardial infarction; Outcomes; β-blocker.

 

 

Original Article : https://saihst.skku.edu/m/24_view.php?bbs_data=aWR4PTUwMjYmbGlzdE5vPTgwJnN0YXJ0UGFnZT0gMA==|| 

 

 

 

조주희, 강단비 우수논문(영문).jpg

Previous Next

List